NCT00999505Unknown3 期
A Double-blind, Randomized, Placebo-controlled Trial With Amantadine as Adjunctive Therapy to Antipsychotics in Schizophrenia
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Scores in Brief Psychiatric Rating Scale
研究概览
简要总结
Amantadine as add-on therapy to antipsychotics may improve schizophrenia positive, negative and cognitive symptoms.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Under antipsychotics with residual symptoms
排除标准
- •Pregnancy
- •Lactation
研究组 & 干预措施
Amantadine
Active Comparator
Amantadine 200mg twice a day
干预措施: Amantadine (Drug)
Placebo
Placebo Comparator
Placebo capsules twice a day
干预措施: Placebo (Drug)
结局指标
主要结局
Scores in Brief Psychiatric Rating Scale
时间窗: Baseline, 4 weeks, 8 weeks, 12 weeks
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety, Blood Levels and Effects of AUT00206SchizophreniaNCT02589262Autifony Therapeutics Limited
已完成
1 期
Safety, Blood Levels and Effects of AUT00201Healthy VolunteerNCT04158453Autifony Therapeutics Limited80
已完成
3 期
Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective DisorderSmoking CessationNCT00644969Pfizer128
招募中
1 期
Acetazolamide for Treatment Resistant SchizophreniaSchizo Affective DisorderSchizophreniaNCT04887792Vishwajit Nimgaonkar, MD PhD60
已完成
不适用
Entacapone Augmentation for SchizophreniaSchizophreniaNCT00192855Rambam Health Care Campus52